Antibodies directed against influenza
Antibodies that specifically bind influenza virus hemagglutinin A (HA), and antigen binding fragments thereof are disclosed herein. In several embodiments, these antibodies are broadly neutralizing. Nucleic acids encoding these monoclonal antibodies, vectors including these nucleic acids, and host cells transformed with these vectors are also disclosed. Compositions are disclosed that include these antibodies, antigen binding fragments, nucleic acids, vectors and host cells. Method of using these antibodies, and antigen binding fragments, nucleic acids, vectors and host cells, such as for diagnosis and treatment of an influenza virus infection are also provided.
1. A non-naturally occurring chimeric antibody, wherein the antibody comprises a heavy chain variable domain and a light chain variable domain,
wherein the heavy chain variable domain comprises the amino acid sequence set forth as SEQ ID NO: 23, the amino acid sequence set forth as SEQ ID NO: 25, and the amino acid sequence set forth as SEQ ID NO: 27 and the light chain variable domain comprises the amino acid sequence set forth as SEQ ID NO: 33, the amino acid sequence KAS, and the amino acid sequence set forth as SEQ ID NO: 37, and
wherein the antibody specifically binds hemagglutinin (HA) of H1N1 and H5N1.
2. The non-naturally occurring chimeric antibody of claim 1 , wherein the antibody specifically binds HA of H3N2.
3. The non-naturally occurring antibody of claim 1 , wherein the heavy chain variable domain comprises an amino acid sequence set forth as SEQ ID NO: 21.
4. The non-naturally occurring chimeric antibody of claim 1 , wherein the light chain variable domain comprises an amino acid sequence set forth as SEQ ID NO: 31.
5. The non-naturally occurring chimeric antibody of claim 1 , wherein the antibody is an IgG, IgM or IgA.
6. The non-naturally occurring chimeric antibody of claim 1 , wherein the antibody is labeled.
7. The non-naturally occurring chimeric antibody of claim 6 , wherein the label is a fluorescent, enzymatic, or radioactive label.
8. A composition comprising an effective amount of the non-naturally occurring chimeric antibody and a pharmaceutically acceptable carrier, wherein the antibody comprises a heavy chain variable domain and a light chain variable domain,
wherein the heavy chain variable domain comprises the amino acid sequence set forth as SEQ ID NO: 23, the amino acid sequence set forth as SEQ ID NO: 25, and the amino acid sequence set forth as SEQ ID NO: 27 and the light chain variable domain comprises the amino acid sequence set forth as SEQ ID NO: 33, the amino acid sequence KAS, and the amino acid sequence set forth as SEQ ID NO: 37, and
wherein the antibody specifically binds hemagglutinin (HA) of H1N1 and H5N1.
9. The composition of claim 8 , wherein the pharmaceutically acceptable carrier is a physiological saline or balanced salt solution.
10. The composition of claim 8 , wherein the pharmaceutically acceptable carrier comprises a buffering agent.
11. The composition of claim 8 , wherein the pharmaceutically acceptable carrier comprises sodium acetate, sodium chloride, potassium chloride, calcium chloride, or sodium lactate.
12. The composition of claim 8 , wherein the pharmaceutically acceptable carrier comprises aqueous dextrose or glycerol.
13. The composition of claim 8 , wherein the pharmaceutically acceptable carrier comprises sorbitan monolaurate.